Nasus Pharma
NSRX
2 hedge funds and large institutions have $21.8K invested in Nasus Pharma in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
1% more capital invested
Capital invested by funds: $21.6K → $21.8K (+$206)
0% more funds holding
Funds holding: 2 → 2 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$6.34K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Morgan Stanley
New York
| $18.3K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $3.46K | -$6.34K | -863 | -70% |
|
NSRX Hedge Fund Activity: Q4 2025 in Review
2 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Nasus Pharma (NSRX) for Q4 2025, worth a combined $21.8K — up 0.96% from $21.6K a quarter earlier.
Fund positioning in NSRX was balanced in Q4 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $6.34K.
- 2 institutional investors held Nasus Pharma (NSRX) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $21.8K of Nasus Pharma stock for Q4 2025, up 0.96% quarter-over-quarter.
- 0 funds opened new Nasus Pharma positions in Q4 2025 and 0 closed out.
- The largest Nasus Pharma seller in Q4 2025 was UBS Group, an estimated $6.34K sold.
Based on aggregated 13F filings for Q4 2025.